Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Séverine Vermeire, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2018Cited by 158
Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's diseaseBram Verstockt, Christine Breynaert, Sare Verstockt et al.|Alimentary Pharmacology & Therapeutics|2019Cited by 72
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD PatientsBram Verstockt, Marc Ferrante, Evelien Mertens et al.|Journal of Crohn s and Colitis|2019Cited by 38
Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patientsNathalie Van den Berghe, Ann Gils, Bram Verstockt et al.|Journal of Gastroenterology and Hepatology|2018Cited by 34
Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseasesClaire Liefferinckx, Denis Franchimont, Ann Gils et al.|United European Gastroenterology Journal|2019Cited by 12